Our Pricing

Tips for Switching From Mounjaro To Wegovy Successfully

If you're considering switching from mounjaro to wegovy uk, understanding the clinical differences between tirzepatide and semaglutide is essential for a smooth transition. At Cured Pharmacy, our UK-registered prescribers assess every patient individually to determine appropriate dosing schedules and monitor for potential side effects during the changeover period.

Why Patients Consider Switching From Mounjaro to Wegovy

Several clinical and practical factors prompt patients to transition from tirzepatide to semaglutide-based treatment. Cost considerations often play a significant role, as Wegovy is priced from £135.00 compared to Mounjaro's starting price of £135.00 at Cured Pharmacy. Some patients also experience supply chain challenges with Mounjaro or find that their insurance coverage favours semaglutide products.

Tolerability differences between the two medications can influence switching decisions. Whilst both are GLP-1 receptor agonists, tirzepatide's dual GIP/GLP-1 mechanism may produce different gastrointestinal side effects compared to semaglutide's single-pathway action [1]. In clinical practice, some patients report better tolerance with one medication over the other, though individual responses vary considerably.

Clinical outcomes from the SURPASS and STEP trials show that tirzepatide typically produces greater average weight loss — up to 22.5% body weight reduction in SURPASS-3 versus 14.9% with semaglutide in STEP-1 [1][2]. However, Wegovy remains highly effective for many patients, and your UK prescriber will assess whether switching aligns with your treatment goals and medical history.

Understanding the Clinical Differences Between Tirzepatide and Semaglutide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA in the UK, whilst Wegovy contains semaglutide, a selective GLP-1 receptor agonist [1][2]. This mechanistic difference means tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, potentially enhancing metabolic effects beyond single-pathway treatments.

Both medications work by slowing gastric emptying, reducing appetite, and improving glycaemic control, but the dual-receptor activation of tirzepatide produces distinct pharmacological effects. The GIP component appears to enhance fat metabolism and may contribute to the greater average weight loss observed in head-to-head comparisons, though direct comparative trials between tirzepatide and semaglutide for weight management are still emerging [3].

Half-life differences also affect dosing schedules. Semaglutide has a half-life of approximately one week, whilst tirzepatide's half-life is around five days. Both are administered as once-weekly subcutaneous injections, but these pharmacokinetic properties influence how quickly each medication reaches steady-state concentrations and how long washout periods should be when switching between treatments.

Receptor Mechanism and Weight Loss Efficacy

The dual GIP/GLP-1 activation mechanism distinguishes tirzepatide from all other currently licensed weight loss medications in the UK. GIP receptors are found predominantly in pancreatic beta cells and adipose tissue, where they influence insulin secretion and fat storage. By targeting both receptor systems simultaneously, tirzepatide may offer enhanced metabolic benefits, though this comes with a different side effect profile that some patients find less tolerable than semaglutide alone [3].

Recommended Dosing Protocol When Switching From Mounjaro to Wegovy UK

There is no direct dose equivalence between tirzepatide and semaglutide, so switching requires careful clinical assessment by a UK prescriber. Most clinicians recommend a washout period of 4-7 days between the last Mounjaro injection and the first Wegovy dose, allowing tirzepatide levels to decline whilst minimising the gap in therapeutic coverage [4].

When transitioning from Mounjaro, your prescriber will typically start you on Wegovy's standard titration schedule beginning with 0.25 mg weekly, regardless of your previous tirzepatide dose. This gradual escalation — moving to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg over 16-20 weeks — helps minimise gastrointestinal side effects and allows your body to adjust to the new medication [2].

Some prescribers may consider a modified titration schedule for patients who were tolerating higher Mounjaro doses (10 mg or 15 mg), potentially shortening the time spent at lower Wegovy doses. However, this decision must be made on an individual basis following thorough clinical assessment. At Cured Pharmacy, our UK prescribers evaluate your complete treatment history, current Mounjaro dose, side effect experience, and weight loss progress before recommending a personalised switching protocol.

Monitoring During the Transition Period

The first 4-6 weeks after switching require close monitoring for changes in side effects, appetite suppression, and weight trajectory. Your prescriber may schedule follow-up consultations to assess tolerance and adjust the titration schedule if needed. Keeping a symptom diary during this period helps identify any adverse reactions early and ensures your treatment remains safe and effective throughout the transition.

Managing Side Effects When Changing From Tirzepatide to Semaglutide

Gastrointestinal side effects — including nausea, vomiting, diarrhoea, and constipation — are the most commonly reported adverse reactions with both medications, though their frequency and severity can differ between tirzepatide and semaglutide [1][2]. Some patients who experienced significant nausea on Mounjaro find semaglutide more tolerable, whilst others report the opposite. Individual variation makes it impossible to predict your specific response without clinical trial.

Starting Wegovy at the lowest dose (0.25 mg) and following the recommended titration schedule significantly reduces the risk of severe gastrointestinal symptoms. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can further minimise nausea and digestive discomfort during the transition period. If side effects become intolerable, your UK prescriber may slow the dose escalation or temporarily reduce your dose.

Injection site reactions may also change when switching medications. Both Mounjaro and Wegovy are administered subcutaneously, but the pen devices and formulation excipients differ slightly. Rotating injection sites between the abdomen, thigh, and upper arm, and ensuring proper injection technique, helps prevent localised irritation and improves medication absorption.

Cost Comparison: Mounjaro vs Wegovy at UK Pharmacies

Pricing differences between tirzepatide and semaglutide can be substantial, particularly for patients funding treatment privately. At Cured Pharmacy, Mounjaro starts from £135.00 per month, whilst Wegovy is available from £135.00 — representing considerable savings over the course of long-term weight management treatment.

Transparent upfront pricing eliminates hidden costs and allows you to budget accurately for your weight loss programme. Unlike some providers who only reveal prices after consultation, Cured Pharmacy displays all treatment costs before you begin your free online assessment. This commitment to pricing transparency, combined with our lowest prices guaranteed policy, ensures you receive genuine UK-licensed medications at competitive rates.

All prescription weight loss treatments at Cured Pharmacy require a clinical assessment by a UK-registered prescriber, which is provided free of charge and typically takes under three minutes to complete. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all dispensing to ensure every prescription meets MHRA standards and GPhC regulatory requirements.

Long-Term Treatment Costs

Weight management with GLP-1 medications typically requires ongoing treatment for sustained results. When comparing annual costs, the price difference between Mounjaro and Wegovy can exceed £135.00 making semaglutide a more economical option for many patients. However, treatment selection should prioritise clinical effectiveness and tolerability alongside cost considerations, as the most affordable medication is only valuable if it produces meaningful weight loss with manageable side effects.

How to Switch From Mounjaro to Wegovy Through Cured Pharmacy

Switching weight loss medications through Cured Pharmacy begins with a free online consultation that takes under three minutes to complete. You'll provide information about your current Mounjaro treatment, including your dose, duration of use, weight loss achieved, and any side effects experienced. This comprehensive medical history allows our UK prescribers to assess whether Wegovy is clinically appropriate for your individual circumstances.

If approved, your Wegovy prescription is dispensed by our UK-registered pharmacy team and delivered in 100% discreet packaging. We stock genuine UK-licensed Wegovy pens manufactured by Novo Nordisk and sourced through authorised UK pharmaceutical wholesalers. Every medication dispensed undergoes quality verification by our superintendent pharmacist to ensure authenticity and proper storage conditions.

Ongoing prescriber support is included with every treatment. If you experience unexpected side effects, have questions about dosing, or need to adjust your titration schedule, our clinical team remains available throughout your weight loss journey. We also provide guidance on diet, exercise, and lifestyle modifications that complement GLP-1 therapy and optimise long-term weight management outcomes.

Prescription Requirements and Clinical Assessment

Wegovy is a prescription-only medication in the UK and cannot be supplied without a valid prescription from a UK-registered prescriber. Our online consultation collects the medical information necessary to make a safe prescribing decision, including your BMI, weight loss history, current medications, and relevant medical conditions. Patients with certain contraindications — such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — may not be suitable candidates for GLP-1 therapy and will be advised of alternative weight management options [2].

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between weight loss treatments.